<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05053867</url>
  </required_header>
  <id_info>
    <org_study_id>2019-0991</org_study_id>
    <nct_id>NCT05053867</nct_id>
  </id_info>
  <brief_title>A Randomized Controlled Trial of Inhaled Tranexamic Acid for the Treatment of Pulmonary Hemorrhage in Cancer Patients</brief_title>
  <official_title>A Randomized Controlled Trial of Inhaled Tranexamic Acid for the Treatment of Pulmonary Hemorrhage in Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a drug study that will examine if inhaled tranexamic acid can improve mortality in&#xD;
      patients with cancer-related pulmonary hemorrhage and respiratory failure as compared to&#xD;
      usual care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective: To assess the benefit of using nebulized tranexamic acid versus the&#xD;
      standard of care on 28 day mortality.&#xD;
&#xD;
      Secondary Objectives: To assess the following outcomes when using nebulized tranexamic acid&#xD;
      versus the standard of care:&#xD;
&#xD;
        1. 90 day, ICU and hospital mortality rate&#xD;
&#xD;
        2. Ventilator days at day 28&#xD;
&#xD;
        3. ICU and Hospital Length of Stay&#xD;
&#xD;
        4. PaO2:FIO2 ratio (or SpO2:FIO2 ratio) changes over the first 14 days&#xD;
&#xD;
        5. Time to resolution of pulmonary hemorrhage&#xD;
&#xD;
        6. Rate of recurrence of pulmonary hemorrhage&#xD;
&#xD;
        7. Rate of invasive procedures required to control pulmonary hemorrhage&#xD;
&#xD;
        8. Changes in Lung Injury Score over the first 14 days following randomization&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>28 day all-cause mortality rate</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Number of patients who are alive at 28 days following randomization. The difference between 28-day mortality rates between treatment arms will be computed along with a 95% confidence interval (CI) using the approximate standard error reported in Fleiss (1981). Logistic regression will be used to estimate the association between 28-day mortality and study covariates of interest.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pulmonary Hemorrhage</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Group A: Inhaled tranexamic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>will receive 500 mg/5ml nebulized tranexamic acid every 8 hours for at least 3 days, and up to 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: Usual Care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>usual care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tranexamic acid</intervention_name>
    <description>Inhaled</description>
    <arm_group_label>Group A: Inhaled tranexamic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <description>Standard of Care</description>
    <arm_group_label>Group B: Usual Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; 18 years old&#xD;
&#xD;
          2. Have a diagnosed hematological malignancy&#xD;
&#xD;
          3. Are actively receiving mechanical ventilation&#xD;
&#xD;
          4. Have evidence of pulmonary hemorrhage as defined by either&#xD;
&#xD;
               1. Persistently bloody secretions upon endotracheal tube suctioning, or&#xD;
&#xD;
               2. Evidence of diffuse alveolar hemorrhage by bronchoscopic examination&#xD;
&#xD;
          5. Signed informed consent by patient or if the subject lacks decision-making capacity,&#xD;
             the subject's legally authorized representative&#xD;
&#xD;
        2.3.2 Exclusion Criteria&#xD;
&#xD;
        Patients excluded from participation in the study if any of the following criteria are met:&#xD;
&#xD;
          1. Presence of a Do Not Resuscitate (DNR), no escalation of care or comfort care order at&#xD;
             the time of screening&#xD;
&#xD;
          2. Expected survival &lt; 48 hours&#xD;
&#xD;
          3. Evidence of nasal or oral spillage likely to be the cause of bloody secretions&#xD;
&#xD;
          4. Patients requiring 100% FIO2&#xD;
&#xD;
          5. Known hypersensitivity to tranexamic acid&#xD;
&#xD;
          6. Treatment with inhaled tranexamic acid prior to screening&#xD;
&#xD;
          7. Acquired defective color vision&#xD;
&#xD;
          8. Subarachnoid hemorrhage&#xD;
&#xD;
          9. Deep Venous or arterial thrombus diagnosed within the previous 3 months&#xD;
&#xD;
         10. Seizure disorder on active anti-epileptic therapies&#xD;
&#xD;
         11. Hypersensitivity to tranexamic acid or any of the ingredients&#xD;
&#xD;
         12. Pregnant women will not be eligible and have a negative pregnancy test prior to&#xD;
             entering study&#xD;
&#xD;
         13. Patient receiving concurrent anti-fibrinolytic therapy&#xD;
&#xD;
         14. Confirmed active COVID-19 infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nisha Rathi</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nisha Rathi</last_name>
    <phone>713-745-5787</phone>
    <email>nrathi@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>M D Anderson Cancer Center</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 2, 2021</study_first_submitted>
  <study_first_submitted_qc>September 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

